GENENTECH, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1976-01-01
- Employees
- 11.1K
- Market Cap
- -
- Website
- http://www.gene.com
Trastuzumab Plus Paclitaxel in Treating Women With Metastatic Breast Cancer That Overexpresses HER2
Phase 2
Completed
- Conditions
- First Posted Date
- 2004-03-16
- Last Posted Date
- 2013-08-20
- Lead Sponsor
- Genentech, Inc.
- Registration Number
- NCT00005635
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
A Study to Evaluate the Safety of Escalating Doses of Ocrelizumab in Subjects With Rheumatoid Arthritis
Phase 1
Completed
- Conditions
- First Posted Date
- 2004-02-16
- Last Posted Date
- 2009-09-03
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 237
- Registration Number
- NCT00077870
Study to Assess the Efficacy and Safety of Rituximab in Patients With Rheumatoid Arthritis
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2003-12-15
- Last Posted Date
- 2013-05-09
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 465
- Registration Number
- NCT00074438
A Study Evaluating Topical Recombinant Human Vascular Endothelial Growth Factor (Telbermin) for Induction of Healing of Chronic, Diabetic Foot Ulcers
Phase 1
Completed
- Conditions
- First Posted Date
- 2003-09-26
- Last Posted Date
- 2017-05-11
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT00069446
Safety and Effect of Pertuzumab in Patients With Advanced Non-Small Cell Lung Cancer, Which Has Progressed After Prior Chemotherapy
- First Posted Date
- 2003-06-25
- Last Posted Date
- 2015-07-07
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 51
- Registration Number
- NCT00063154
- Locations
- 🇺🇸
Memorial-Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸University of California Davis Cancer Center, Sacramento, California, United States
🇺🇸Arizona Cancer Center, Tucson, Arizona, United States
A Study to Compare rhuFab V2 With Verteporfin Photodynamic in Treating Subfoveal Neovascular Macular Degeneration
Phase 3
Completed
- Conditions
- First Posted Date
- 2003-05-30
- Last Posted Date
- 2014-03-19
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 426
- Registration Number
- NCT00061594
- Locations
- 🇺🇸
Doheny Eye Institute, Los Angeles, California, United States
🇺🇸Midwest Retina, Columbus, Ohio, United States
🇺🇸Wills Eye Hospital, Philadelphia, Pennsylvania, United States
Efficacy and Safety Study of rhuMAb VEGF to Treat Metastatic Renal Cell Carcinoma
Phase 3
Withdrawn
- Conditions
- First Posted Date
- 2003-05-23
- Last Posted Date
- 2016-10-19
- Lead Sponsor
- Genentech, Inc.
- Registration Number
- NCT00061178
Safety and Efficacy Study of Pertuzumab to Treat Castration-Resistant Prostate Cancer
Phase 2
Completed
- Conditions
- First Posted Date
- 2003-04-09
- Last Posted Date
- 2015-06-23
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 42
- Registration Number
- NCT00058539
A Study to Evaluate the Effect of HER2 Activation on rhuMAb 2C4 (Pertuzumab) in Subjects With Advanced Ovarian Cancer
Phase 2
Completed
- Conditions
- First Posted Date
- 2003-04-09
- Last Posted Date
- 2017-03-08
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 129
- Registration Number
- NCT00058552
Intravitreal Injections of rhuFab V2 in Combination With Visudyne in Subjects With Age Related Macular Degeneration (AMD)
Phase 1
Completed
- Conditions
- First Posted Date
- 2003-03-26
- Last Posted Date
- 2013-06-21
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 168
- Registration Number
- NCT00056823
© Copyright 2024. All Rights Reserved by MedPath